特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場アクセスへの影響力:乾癬 (欧州主要5ヶ国)

Market Access Impact: Psoriasis (EU5) 2018

発行 FirstWord 商品コード 629540
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
市場アクセスへの影響力:乾癬 (欧州主要5ヶ国) Market Access Impact: Psoriasis (EU5) 2018
出版日: 2018年02月01日 ページ情報: 英文
概要

当レポートでは、欧州主要5ヶ国 (フランス・ドイツ・イタリア・スペイン・英国) で乾癬の治療に従事している医療専門家100名に対するアンケート調査の結果に基づいて、潰瘍性大腸炎の治療薬の利用への影響要因について分析すると共に、主要企業の市場シェア構造や、各社が現在直面している主な障害 (市場アクセスなど) とその原因・影響、取るべき対応策といった情報を取りまとめてお届けいたします。

分析対象製品:乾癬の主な治療薬

  • Benepali (エタネルセプト;Biogen)
  • Cosentyx (セクキヌマブ;Novartis)
  • Enbrel (エタネルセプト;Pfizer)
  • Erelzi (エタネルセプト;Sandoz)
  • Humira (アダリムマブ;AbbVie)
  • Kyntheum (ブロダルマブ;Leo Pharma)
  • Otezla (アプレミラスト;Celgene)
  • Stelara (ウステキヌマブ;Janssen Cilag)
  • Taltz (イキセキズマブ;Eli Lilly)
  • Tremfya (グセルクマブ;Janssen Cilag)

目次

  • 「市場障壁」とは何か?
  • 当レポートについて
  • 今回の分析について
  • 調査対象のブランド
  • エグゼクティブ・サマリー
目次

Market barriers affect just over a fifth of psoriasis prescriptions. Is your brand losing out?

In the EU5, market barriers affect just over a fifth of all psoriasis prescriptions, with the top brand way ahead of its two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last place brand double its share in Market Access Impact: Psoriasis (EU5) [2018].

Based on a survey of 150 dermatologists, the report covers 10 major therapies from Novartis, AbbVie, Celgene, Leo Pharma, Janssen Cilag, Biogen, Pfizer and Eli Lilly. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just over a fifth of all prescriptions: But two barriers in particular affect more prescriptions than the others.
  • Market access is not the problem: Barriers related to market access affect far fewer prescriptions than either of the top two barriers. What are they and what can be done about them?
  • Three brands gain share: But the most prescribed brand sees a significantly larger net gain than any other brand.
  • One brand loses big: One of the least-prescribed brands loses far more market share than any competitor, and suffers disproportionately from three of the seven barriers.
  • Eliminating barriers would close the gaps, but not the rankings: By removing certain barriers, certain brands could improve market share and get closer to rivals. What do you need to do for your brand, and what difference would it make?
  • Two brands have a perception problem: Just over 10% of surveyed doctors didn't even know these two brands exist.

Insight into 10 Major Psoriasis Drugs

  • Benepali (etanercept; Biogen)
  • Cosentyx (secukinumab; Novartis)
  • Enbrel (etanercept; Pfizer)
  • Erelzi (etanercept; Sandoz)
  • Humira (adalimumab; AbbVie)
  • Kyntheum (brodalumab; Leo Pharma)
  • Otezla (apremilast; Celgene)
  • Stelara (ustekinumab; Janssen Cilag)
  • Taltz (ixekizumab; Eli Lilly)
  • Tremfya (guselkumab; Janssen Cilag)

Exploring Market Access Barriers

Market Access Impact: Psoriasis (EU5) explores key issues affecting Psoriasis drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 dermatologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between February 6-15, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

  • 1. What are market barriers?
  • 2. About this report
  • 3. About the survey
  • 4. Brands included in the survey
  • 5. Executive summary